Hot Flashes: Aetiology and Management

Overview

Journal Drugs Aging

Specialties Geriatrics
Pharmacology

Date 2001 Oct 6

PMID 11587246

Citations 7

Authors

D Barton

C Loprinzi

D Wahner-Roedler

Affiliations

Soon will be listed here.

Abstract

Menopause, an event often accompanied by symptoms such as hot flashes, can have a significant impact on a woman's quality of life. A majority of women will experience hot flashes at some point in their life, given a normal life span. Despite multiple theories, the exact pathophysiology of hot flashes is not yet known. Many types of treatment options exist for women with hot flashes, from hormonal and nonhormonal pharmacological therapies to nonpharmacological interventions. Choosing the best treatment option for specific women involves knowledge of the risks and benefits of each treatment. Hormones (estrogen and/or progesterone, or tibolone alone) are still the most effective option available, resulting in an 80 to 90% reduction in hot flashes. The best nonhormonal treatment to date is in the class of newer antidepressants that comprises various selective reuptake inhibitors; for example, venlafaxine provides about a 60% reduction in hot flashes. This article provides evidence-based information about available treatment options for hot flash management, with special consideration of populations such as breast cancer survivors.

Citing Articles

Resistance training reduced luteinising hormone levels in postmenopausal women in a substudy of a randomised controlled clinical trial: A clue to how resistance training reduced vasomotor symptoms.

Nilsson S, Henriksson M, Berin E, Engblom D, Holm A, Hammar M PLoS One. 2022; 17(5):e0267613.

PMID: 35617333 PMC: 9135255. DOI: 10.1371/journal.pone.0267613.

The Beneficial and Adverse Effects of Raloxifene in Menopausal Women: A Mini Review.

Khorsand I, Kashef R, Ghazanfarpour M, Mansouri E, Dashti S, Khadivzadeh T J Menopausal Med. 2019; 24(3):183-187.

PMID: 30671411 PMC: 6336572. DOI: 10.6118/jmm.2018.24.3.183.

Relaxation for perimenopausal and postmenopausal symptoms.

Saensak S, Vutyavanich T, Somboonporn W, Srisurapanont M Cochrane Database Syst Rev. 2014; (7):CD008582.

PMID: 25039019 PMC: 11094687. DOI: 10.1002/14651858.CD008582.pub2.

Management of menopause-associated vasomotor symptoms: Current treatment options, challenges and future directions.

Pachman D, Jones J, Loprinzi C Int J Womens Health. 2010; 2:123-35.

PMID: 21072305 PMC: 2971731. DOI: 10.2147/ijwh.s7721.

Acupuncture for hot flashes in patients with prostate cancer.

Beer T, Benavides M, Emmons S, Hayes M, Liu G, Garzotto M Urology. 2010; 76(5):1182-8.

PMID: 20494414 PMC: 2928879. DOI: 10.1016/j.urology.2010.03.033.

References

Freedman R . Biochemical, metabolic, and vascular mechanisms in menopausal hot flashes. Fertil Steril. 1998; 70(2):332-7. DOI: 10.1016/s0015-0282(98)00137-x. View

Nand S, Webster M, Baber R, Heller G . Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group. Climacteric. 2002; 1(3):211-8. DOI: 10.3109/13697139809085543. View

Vercellini P, Vendola N, Colombo A, Passadore C, Trespidi L, Crosignani P . Veralipride for hot flushes during gonadotropin-releasing hormone agonist treatment. Gynecol Obstet Invest. 1992; 34(2):102-4. DOI: 10.1159/000292736. View

Wyon Y, Spetz A, Theodorsson G, Hammar M . Concentrations of calcitonin gene-related peptide and neuropeptide Y in plasma increase during flushes in postmenopausal women. Menopause. 2000; 7(1):25-30. DOI: 10.1097/00042192-200007010-00005. View

Wren B, Brown L . A double-blind trial with clonidine and a placebo to treat hot flushes. Med J Aust. 1986; 144(7):369-70. DOI: 10.5694/j.1326-5377.1986.tb115924.x. View

Tataryn I, LOMAX P, Bajorek J, Chesarek W, Meldrum D, Judd H . Postmenopausal hot flushes: a disorder of thermoregulation. Maturitas. 1980; 2(2):101-7. DOI: 10.1016/0378-5122(80)90043-2. View

Pronzato P, Brema F, Amoroso D, Bertelli G, Conte P, Martini M . Megestrol acetate: phase II study of a single daily administration in advanced breast cancer. Breast Cancer Res Treat. 1990; 17(1):51-4. DOI: 10.1007/BF01812684. View

Bullock J, MASSEY F, Gambrell Jr R . Use of medroxyprogesterone acetate to prevent menopausal symptoms. Obstet Gynecol. 1975; 46(2):165-8. View

Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K . A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol. 1998; 105(8):904-11. DOI: 10.1111/j.1471-0528.1998.tb10237.x. View

10.

Finck G, Barton D, Loprinzi C, Quella S, Sloan J . Definitions of hot flashes in breast cancer survivors. J Pain Symptom Manage. 1998; 16(5):327-33. DOI: 10.1016/s0885-3924(98)00090-6. View

11.

Gundersen S, KVINNSLAND S, Lundgren S, Klepp O, Lund E, Bormer O . Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 1990; 17(1):45-50. DOI: 10.1007/BF01812683. View

12.

Martoni A, Longhi A, Canova N, Pannuti F . High-dose medroxyprogesterone acetate versus oophorectomy as first-line therapy of advanced breast cancer in premenopausal patients. Oncology. 1991; 48(1):1-6. DOI: 10.1159/000226884. View

13.

Albertazzi P, Di Micco R, Zanardi E . Tibolone: a review. Maturitas. 1999; 30(3):295-305. DOI: 10.1016/s0378-5122(98)00059-0. View

14.

Castelo-Branco C, Figueras F, Sanjuan A, Vicente J, Martinez de Osaba M, Pons F . Long-term compliance with estrogen replacement therapy in surgical postmenopausal women: benefits to bone and analysis of factors associated with discontinuation. Menopause. 1999; 6(4):307-11. DOI: 10.1097/00042192-199906040-00006. View

15.

Loprinzi C, Michalak J, Quella S, OFallon J, Hatfield A, Nelimark R . Megestrol acetate for the prevention of hot flashes. N Engl J Med. 1994; 331(6):347-52. DOI: 10.1056/NEJM199408113310602. View

16.

Quella S, Loprinzi C, Sloan J, Vaught N, DeKrey W, Fischer T . Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998; 82(9):1784-8. View

17.

Loprinzi C, Pisansky T, Fonseca R, Sloan J, Zahasky K, Quella S . Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol. 1998; 16(7):2377-81. DOI: 10.1200/JCO.1998.16.7.2377. View

18.

Verbeke K, Dhont M, Vandekerckhove D . Clinical and hormonal effects of long-term veralipride treatment in post-menopausal women. Maturitas. 1988; 10(3):225-30. DOI: 10.1016/0378-5122(88)90025-4. View

19.

Carpenter J, Andrykowski M . Menopausal symptoms in breast cancer survivors. Oncol Nurs Forum. 1999; 26(8):1311-7. View

20.

Quella S, Loprinzi C, Barton D, Knost J, Sloan J, Lavasseur B . Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 2000; 18(5):1068-74. DOI: 10.1200/JCO.2000.18.5.1068. View